Kelun-Biotech hopes for IPO booster from new Merck partnership
The company welcomed Merck as new shareholder not long after the pair signed a lucrative licensing agreement for its cutting-edge ADC cancer treatment Key Takeaways: Despite a lack of products…
Recent Articles
RELATED ARTICLES
-
HBM gets health boost from drug licensing deals
2142.HK -
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
-
RemeGen hopes for pain relief from expanded drug uses
9995.HK 688331.SHG
-
Akeso marks profit milestone with swift rights issue
9926.HK
- InSilico seeks IPO boost to get AI drugs over the line
